Table 3

Methodological information of 1096 RCTs on Traditional Chinese Medicine from International Trial Registries

Items|CHM N=290 (%)Acupuncture/ acupressure N=509 (%)Qigong/Taichi N=66 (%)Tuina N=65 (%)Other therapies N=166 (%)Total
Design
 Parallel269 (92.8)477 (93.7)62 (93.9)54 (83.1)162 (97.6)1024
 Crossover17 (5.9)24 (4.7)3 (4.6)9 (13.9)2 (1.2)55
 Phase II/III*120/172 (69.8)141/186 (75.8)20/24 (83.3)21/24 (87.5)30/68 (44.1)332
Placebo/sham-controlled194 (66.9)228 (44.8)0 (0.00)0 (0.00)41 (24.7)463
Sample size estimation287 (99.0)496 (97.5)64 (97.0)65 (100.0)164 (98.8)1076
Generation of allocation sequence114 (39.3)63 (12.4)8 (12.1)8 (12.3)85 (51.2)278
Allocation concealment47 (16.2)34 (6.7)4 (6.1)8 (12.3)11 (6.6)104
Blinding219 (75.5)346 (68.0)40 (60.6)38 (58.5)71 (42.8)714
TCM syndrome differentiation65 (22.4)†
  • *Only 474 trials (43.2%) provided information about phase.

  • Blinding included participants, personnel and/or outcome assessors blinded.

  • †TCM syndrome differentiation (bian zheng lun zhi): data limited to CHM.

  • CHM: Chinese herbal medicine; RCTs, randomised clinical trials; TCM, Traditional Chinese Medicine.